Overview

Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer

Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Patient receiving oxaliplatin and docetaxel will have longer progression free survival than those patients receiving standard care.
Phase:
Phase 2
Details
Lead Sponsor:
Minneapolis Veterans Affairs Medical Center
Collaborator:
Sanofi
Treatments:
Docetaxel
Oxaliplatin